Actavis plc, of Dublin, said the FDA accepted for filing the firm's ceftazidime-avibactam, its investigational antibiotic for the treatment of patients with complicated urinary tract Infections and complicated intra-abdominal infections, including those caused by multidrug-resistant gram-negative bacterial pathogens.